Table 3.

Adverse events during treatment

	NDP group (n = 78)				DDP group (n = 79)				P value
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Hematological
Leukopenia	30 (38.46)	18 (23.08)	4 (5.13)	0	31 (39.24)	26 (32.91)	6 (7.59)	0	0.247
Neutropenia	13 (16.67)	10 (12.82)	3 (3.85)	1 (1.28)	22 (27.84)	6 (7.59)	2 (2.53)	1 (1.27)	0.463
Anemia	35 (44.87)	4 (5.13)	0	0	34 (43.04)	1 (1.27)	0	0	0.350
Thrombocytopenia	3 (3.85)	1 (1.28)	0	0	4 (5.06)	1 (1.27)	0	0	0.934
Lymphopenia	7 (8.97)	27 (34.62)	41 (52.56)	0	4 (5.06)	25 (31.65)	47 (59.49)	3	0.192
Non-hematological
Vomiting	20 (25.64)	16 (20.51)	4 (5.13)	0	30 (37.97)	22 (27.84)	9 (11.39)	0	0.021∗
Nausea	21 (26.92)	18 (23.08)	5 (6.41)	0	32 (40.51)	24 (30.38)	11 (13.92)	0	0.009∗
Anorexia	23 (29.49)	22 (28.21)	7 (8.97)	0	33 (41.77)	25 (31.65)	13 (16.46)	0	0.011∗
Constipation	10 (12.82)	5 (6.41)	0	0	12 (15.19)	7 (8.87)	0	0	0.473
Diarrhea	22 (28.21)	8 (10.26)	0	0	23 (29.11)	9 (11.39)	0	0	0.387
Hiccups	2 (2.56)	0	0	0	2 (2.53)	0	0	0	0.942
Weight loss	30 (38.46)	12 (15.38)	1 (1.28)	0	34 (43.04)	14 (17.72)	3	0	0.041∗
Fatigue	7 (8.97)	6 (7.69)	0	0	7 (8.86)	7 (8.86)	0	0	0.849
Fever	2 (2.56)	1 (1.28)	0	0	3 (3.80)	0	0	0	0.904
Total bilirubin	6 (7.69)	1 (1.28)	0	0	2 (2.53)	1 (1.27)	0	0	0.034∗
ALT increase	6 (7.69)	1 (1.28)	0	0	1 (1.27)	1 (1.27)	0	0	0.044∗
AST increase	5 (6.41)	1 (1.28)	0	0	1 (1.27)	1 (1.27)	0	0	0.046∗
Creatinine increase	0	0	0	0	4 (5.06)	0	0	0	<0.001∗

Data are n (%). No grade 5 adverse events occurred during treatment. As prespecified by protocol, differences in adverse events were analyzed using χ² test.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; DDP, cisplatin; NDP, nedaplatin.

^∗P < 0.05 is considered significant.